Soluble CD25 in Hemophagocytic Lymphohistiocytosis: Diagnostic Use and Anti-CD25 Treatment
Diagnostic Role of Soluble CD25
Soluble CD25 (sCD25) ≥2400 U/mL is one of the 8 diagnostic criteria in the HLH-2004 guidelines, and you need 5 of 8 criteria to diagnose HLH. 1
Performance as a Diagnostic Marker
sCD25 outperforms ferritin as a diagnostic test for adult HLH, with an area under the curve of 0.90 (95% CI: 0.83-0.97) compared to ferritin's 0.78 (95% CI: 0.67-0.88). 1
The test is characterized as a "good to excellent low-cost diagnostic test" for adult HLH and should be obtained in all patients with suspected HLH. 1
sCD25 is part of the characteristic laboratory profile of HLH, which includes elevated ferritin, triglycerides, transaminases, lactate dehydrogenase, and d-dimers, along with decreased fibrinogen, albumin, and sodium. 2
Clinical Context and Interpretation
Do not delay treatment waiting for sCD25 results if clinical suspicion is high - HLH-directed therapy may be initiated even when fewer than 5 diagnostic criteria are met if the clinical picture is compelling. 1
sCD25 elevation reflects excessive immune activation from cytotoxic T cells, natural killer cells, and macrophages that characterizes HLH pathophysiology. 2
In critically ill patients, elevated sCD25 correlates with other markers of severe hyperinflammation including thrombocytopenia (rs=-0.421, P=0.018), hypoalbuminemia (rs=-0.678, P<0.001), and need for life support treatments (rs=0.479, P=0.006). 3
Prognostic Value
sCD25 is an independent adverse prognostic factor in adult HLH - in multivariate analysis of 62 adult patients, sCD25 was the only significant prognostic marker (P=0.005) predicting overall survival. 4
The OHI (Optimized HLH Inflammatory) index, which combines sCD25 >3900 U/mL with ferritin >1000 ng/mL, predicts mortality more effectively than conventional HLH criteria in lymphoma patients, with OHI-positive patients showing 13-fold increased mortality risk. 5
OHI-positive lymphoma patients have 1-year survival of only 33% vs 81% in OHI-negative patients, with 58% dying from multiorgan failure rather than lymphoma progression. 5
Recommended Treatment Approach
Standard HLH Treatment
The primary treatment for HLH follows the HLH-2004 protocol, which typically includes dexamethasone, etoposide, and cyclosporine A, with treatment directed at both the hyperinflammation and any underlying trigger. 1
In lymphoma-associated HLH with elevated sCD25, incorporating etoposide into lymphoma-directed treatment improves survival - this was specifically demonstrated in OHI-positive T-cell lymphomas (P=0.007). 5
Trigger identification and treatment is mandatory, including screening for malignancy (which increases dramatically with age, reaching 68% in adults >60 years), infections (especially EBV and CMV), and autoimmune conditions. 2, 6
Role of Anti-CD25 Antibodies
Daclizumab (anti-CD25 monoclonal antibody) has been used successfully in steroid-dependent adult HLH as salvage therapy, allowing withdrawal of steroids without symptom recurrence. 7
The rationale for anti-CD25 therapy is that sCD25 elevation reflects disease activity, though its exact pathophysiologic role remains unclear. 7
This represents a case report level of evidence (single adult patient), so anti-CD25 antibodies should be considered experimental salvage therapy rather than first-line treatment. 7
Anti-CD25 therapy may be considered in patients with refractory or steroid-dependent HLH who have failed standard immunosuppressive approaches. 7
Treatment Monitoring
Monitor sCD25 levels along with ferritin to assess disease activity and treatment response, as both markers reflect ongoing hyperinflammation. 1, 4
Platelet count drops rapidly with disease flares and should be monitored every 12-24 hours along with temperature, spleen size, and liver function tests. 6
Ferritin increases rapidly in active HLH but normalizes slowly, so use it in combination with other markers rather than in isolation. 6
Critical Diagnostic Pitfalls
HLH presents identically to sepsis or multiple organ dysfunction syndrome - maintain high index of suspicion in critically ill patients with unexplained hyperinflammation. 6
Only 7.1% of pediatric patients dying from severe sepsis had sCD25 >2400 U/mL despite 35.7% meeting ≥5 HLH-2004 criteria, demonstrating significant overlap between sepsis and HLH. 8
Hemophagocytosis may be absent on initial bone marrow examination - do not rule out HLH based solely on its absence; perform serial aspirates or examine other organs if clinical suspicion remains high. 1, 6
The HLH-2004 criteria were developed for children and are not formally validated in adults, though they remain the standard diagnostic approach requiring clinical judgment. 1